Skip to main content

Table 3 Impact of early pharmacological treatment on rate of FEV1 decline

From: What have we learned from observational studies and clinical trials of mild to moderate COPD?

Study Participants Follow-up Intervention Outcome
Scanlon PD et al. [72] 3926 smokers 5 years Quitting smoking Improvement in FEV1 (47 ml or 2%)
Decreamer M, et al. [66] 2375 GOLD II 4 years Tiotropium vs. placebo Reduction in rate of FEV1 decline (43 ml/year vs. 49 ml/year, p = 0.024)
Troosters T et al. [73] 120 GOLD II 4 years Tiotropium vs. placebo Reduction in rate of FEV1 decline (35 ml vs. 45 ml)
Zhou Y et al. [74] 841 GOLD I and II 2 years Tiotropium vs. placebo Reduction in rate of FEV1 decline (29 ml vs. 51 ml)
Jenkins CR et al. [63] 2156 GOLD II 3 years SFC vs. placebo Reduction in rate of FEV1 decline (difference 16 ml/year, 95% CI 0,32)
Calverley PMA, et al. [75] 6981 GOLD II 15 to 44 months SFC vs. placebo Reduction in rate of FEV1 decline (38 ml vs −46 ml, p = 0.019))
  1. FEV1 forced expiratory volume in one second, SFC salmeterol/fluticasone fixed dose combination